Pomalidomide-C9-CO2H is primarily utilized in the development of novel therapeutic agents, particularly in the field of oncology. It serves as a key intermediate in the synthesis of targeted cancer therapies, especially those designed to treat multiple myeloma and other hematologic malignancies. The compound is often employed in the creation of proteolysis-targeting chimeras (PROTACs), which are innovative molecules that degrade specific disease-causing proteins by harnessing the cell's natural degradation machinery. This approach enhances the precision of cancer treatment, minimizing off-target effects. Additionally, Pomalidomide-C9-CO2H is used in research to study the mechanisms of immunomodulation and angiogenesis inhibition, contributing to the advancement of treatments for various cancers and inflammatory diseases. Its role in drug development underscores its importance in creating more effective and targeted therapies for complex diseases.